Introduction
The United Arab Emirates has taken a significant step forward in regulating its healthcare sector with the introduction of Federal Decree-Law No. (38) of 2024 Governing Medical Products, Pharmacists and Pharmaceutical Establishments. This comprehensive legislation, signed by His Highness Sheikh Mohammed Bin Zayed Al Nahyan, President of the UAE, marks a pivotal moment in the country’s ongoing efforts to enhance healthcare standards, ensure patient safety, and promote innovation in the pharmaceutical industry.
Scope and Objectives
The new law encompasses a wide range of areas within the healthcare and pharmaceutical sectors. Its primary objectives include:
- Regulating the manufacture, import, export, storage, distribution, and sale of medical products.
- Establishing standards for pharmacists and pharmaceutical establishments.
- Ensuring the quality, safety, and efficacy of medical products available in the UAE.
- Promoting transparency and ethical practices in the pharmaceutical industry.
Key Legal Provisions
Definition and Classification of Medical Products
The law provides a comprehensive definition of “Medical Products” in Article (2), which includes:
- Pharmaceutical products
- Medical devices and supplies
- Health supplements and herbal products
- Cosmetics and personal care products
This broad definition ensures that the law covers a wide spectrum of products used in healthcare settings and by consumers, providing a unified regulatory framework.
Establishment of the Emirates Drug Establishment (EDE)
One of the most significant aspects of this law is the formal recognition and empowerment of the Emirates Drug Establishment (EDE). The EDE is granted extensive authority to:
- Develop and implement policies related to medical products.
- Issue licenses for pharmaceutical establishments and professionals.
- Conduct inspections and quality control measures.
- Enforce regulations and impose penalties for non-compliance.
This centralization of authority under the EDE is expected to streamline regulatory processes and enhance consistency in the application of standards across the UAE.
Licensing and Registration Requirements
The law stipulates stringent licensing requirements for:
- Pharmaceutical establishments (including manufacturers, distributors, and retail pharmacies)
- Pharmacists and other pharmaceutical professionals
- Medical products
These provisions aim to ensure that only qualified entities and individuals operate within the sector and that all medical products meet the required safety and efficacy standards before entering the market.
Good Manufacturing Practices (GMP) and Quality Control
Articles within the law emphasize the importance of adhering to Good Manufacturing Practices (GMP) for pharmaceutical products. Manufacturers are required to implement robust quality control systems and undergo regular inspections to maintain their licenses.
Pharmacovigilance and Post-Market Surveillance
The legislation introduces comprehensive pharmacovigilance requirements, mandating the reporting of adverse events and the continuous monitoring of medical products post-market launch. This proactive approach aims to quickly identify and address any safety concerns that may arise after a product has been approved for use.
Regulation of Clinical Trials
The law includes provisions for the regulation of clinical trials conducted within the UAE. It outlines the approval process, ethical considerations, and safety measures required for conducting human subject research, aligning the UAE with international standards in clinical research.
Penalties and Enforcement
A significant portion of the law is dedicated to enforcement measures and penalties for non-compliance. These include:
- Fines ranging from AED 10,000 to AED 1,000,000 for various violations.
- Temporary or permanent closure of non-compliant establishments.
- Revocation of licenses for serious or repeated infractions.
- Criminal penalties for actions that endanger public health.
These strict enforcement provisions underscore the UAE’s commitment to maintaining high standards in the healthcare and pharmaceutical sectors.
Impact on Stakeholders
Pharmaceutical Companies
Pharmaceutical companies operating in the UAE will need to adapt to the new regulatory landscape. This includes:
- Updating their quality management systems to comply with new standards.
- Enhancing their pharmacovigilance capabilities.
- Ensuring all products meet the new registration and labeling requirements.
Healthcare Professionals
Pharmacists and other healthcare professionals will be subject to more rigorous licensing and continuing education requirements. The law emphasizes the importance of professional development and adherence to ethical standards.
Consumers
The law aims to benefit consumers by ensuring access to safe, high-quality medical products. Enhanced labeling requirements and stricter control over the sale of prescription medications are expected to improve patient safety and reduce the risk of medication errors.
International Alignment and Recognition
The Federal Decree-Law No. (38) of 2024 aligns the UAE’s regulatory framework with international best practices. This alignment is crucial for:
- Facilitating international trade in pharmaceutical products.
- Attracting foreign investment in the UAE’s pharmaceutical sector.
- Enhancing the global recognition of UAE-manufactured medical products.
Conclusion
Federal Decree-Law No. (38) of 2024 represents a comprehensive overhaul of the UAE’s approach to regulating medical products, pharmacists, and pharmaceutical establishments. By establishing clear standards, empowering regulatory bodies, and implementing strict enforcement measures, the UAE is positioning itself as a leader in healthcare regulation in the Middle East.
As the law comes into effect, it will undoubtedly present challenges for stakeholders in adapting to the new requirements. However, the long-term benefits in terms of improved public health, enhanced patient safety, and increased confidence in the UAE’s healthcare system are expected to far outweigh these initial hurdles.
Stakeholders in the healthcare and pharmaceutical sectors are advised to thoroughly familiarize themselves with the provisions of this new law and take proactive steps to ensure compliance. As the regulatory landscape continues to evolve, staying informed and adaptable will be key to success in the UAE’s dynamic healthcare market.
Having said that, Contact Khairallah Advocates & Legal Consultants and benefit from our free 30-min legal consultation.
*Disclaimer: our blogs, law updates and FAQ’s are freely distributed for educational purposes and to showcase recent updates and regulations in the UAE’s framework.
If you have any questions and need assistance, contact us at our number or book an appointment online.
